A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

NCT07281001 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer
Trastuzumab Deruxtecan

Interventions

DRUG: T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.

Sponsor

Blokhin's Russian Cancer Research Center